本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600211 证券简称：西藏药业 公告编号：2026-002 西藏诺迪康药业股份有限公司 关于为控股子公司提供担保的进展公告 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公 司对外担保总额（万元） | 80,000 | | 对外担保总额占上市公司最近一期经 审计净资产的比例（%） | 20.24% | | 特别风险提示 | □对外担保总额（含本次）超过上市公司最近一期 | | | 经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最近一期 | | | 经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达到或超 | | | 过最近一期经审计净资产 30% | | | 70%的单位提供担保 ☑本次对资产负债率超过 | 注：本次担保中，仅全资子公司生物医药资产负债率超过 70%。 一、担保情况概述 （一）担保的基本情况 重要内容提示： 根据本公司生产经营及 ...

Core Viewpoint - During the "14th Five-Year Plan" period, Tibet Pharmaceutical has established itself as a benchmark enterprise in the Tibetan medicine industry, focusing on innovation and responsibility while achieving significant results in the modernization and high-quality development of ethnic medicine [1][2] Group 1: Business Development - Tibet Pharmaceutical has built an industrial layout covering Tibet, Sichuan, Shanghai, Hong Kong, and overseas, with multiple subsidiaries and a full-chain management platform [1] - The company’s core products focus on cardiovascular treatments, forming an industrial pattern that integrates biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs [1] - In 2024, Tibet Pharmaceutical achieved a revenue of 2.807 billion yuan, with a compound annual growth rate of 20% over the past five years; net profit attributable to shareholders was 1.051 billion yuan, a year-on-year increase of 31.26% [1] Group 2: Product Innovation - Tibet Pharmaceutical has achieved several industry firsts, including the self-developed "New Active Substance" (recombinant human brain natriuretic peptide injection), which is the first gene-engineered new drug for acute heart failure in China [1] - The exclusive Tibetan medicine "Nodikon Capsule" has been included in the national essential drug list and medical insurance directory, marking a significant product in the modernization of Tibetan medicine [1] - The acquisition of "Imdur" (isosorbide mononitrate sustained-release tablets) from AstraZeneca for $190 million enhances the company's portfolio of cardiovascular drugs [1] Group 3: Future Plans and Social Responsibility - In 2025, Tibet Pharmaceutical plans to invest $60 million in Ruizheng Gene to enter the gene editing sector, with its product ART001 recognized as an orphan drug by the FDA [2] - The company has invested 300 million yuan in Morningstar Pharmaceuticals to secure exclusive commercial sales rights for the lung cancer drug "Zolmitriptan" in mainland China, preparing for long-term growth [2] - Tibet Pharmaceutical has integrated social responsibility into its operations, contributing a total tax amount of 2.899 billion yuan, with 2.608 billion yuan paid in Tibet, and donating over 70 million yuan in medicines and materials [2] - Looking ahead to the "15th Five-Year Plan," Tibet Pharmaceutical aims to pursue growth through both internal development and external expansion, while continuing to contribute unique value to the pharmaceutical industry [2]

从资金流向上来看，当日生物制品板块主力资金净流入1.91亿元，游资资金净流出2.73亿元，散户资金净 流入8203.94万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002773 康弘药业 | | 1.18 Z | 18.31% | -3021.77万 | -4.70% | -8748.13万 | -13.61% | | 000661 | 长春高新 | 7444.34万 | 9.43% | -4755.38万 | -6.02% | -2688.95万 | -3.40% | | 688331 荣昌生物 | | 6982.31万 | 10.14% | -2366.87万 | -3.44% | -4615.43万 | -6.71% | | 300122 智飞生物 | | 3724.35万 | 9.83% | 85.58万 | 0.23% | -3809.93万 | -10.05% ...

每经AI快讯，西藏药业1月5日晚间发布公告称，2026年1月5日，公司通过上海证券交易所交易系统以 集中竞价交易方式首次回购公司股份3800股，占公司总股本的比例为0.0012%，购买的最高价为42.99 元/股，最低价为42.95元/股，已支付的总金额为人民币约16万元。 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 （记者 王晓波） ...

证券代码：600211 证券简称：西藏药业 公告编号：2026-001 西藏诺迪康药业股份有限公司 关于首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/19，由董事会提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 18 12 | 12 | 月 | 日~2026 | 年 | 月 | 17 | 日 | | 预计回购金额 | 17,000万元~20,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 3,800股 | | | | | | | | | 累计已回购股数占总股本比 ...

格隆汇1月5日丨西藏药业(600211.SH)公布，2026年1月5日，公司通过上海证券交易所交易系统以集中 竞价交易方式首次回购公司股份3800股，占公司总股本的比例为0.0012%，购买的最高价为42.99元/ 股，最低价为42.95元/股，已支付的总金额为人民币163,278.00元（不含印花税、交易佣金等交易费 用）。 ...

格隆汇1月5日丨西藏药业(600211.SH)公布，2026年1月5日，公司通过上海证券交易所交易系统以集中 竞价交易方式首次回购公司股份3800股，占公司总股本的比例为0.0012%，购买的最高价为42.99元/ 股，最低价为42.95元/股，已支付的总金额为人民币163,278.00元（不含印花税、交易佣金等交易费 用）。 ...

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.34% on December 30, with Wanze Co., Ltd. leading the losses. The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1]. Group 1: Market Performance - The biopharmaceutical sector's performance showed mixed results, with individual stocks experiencing varying degrees of gains and losses. Notably, Aidi Pharmaceutical saw a rise of 4.10% to close at 15.98, while Wanze Co., Ltd. fell by 6.76% to 21.94 [1][2]. - The trading volume for Aidi Pharmaceutical was 93,900 shares, with a transaction value of 150 million yuan, indicating strong investor interest [1]. Group 2: Capital Flow - The biopharmaceutical sector faced a net outflow of 330 million yuan from institutional investors, while retail investors contributed a net inflow of 349 million yuan, suggesting a shift in investor sentiment [2]. - The data indicates that while institutional investors withdrew funds, retail investors were more active in purchasing shares within the sector [2][3]. Group 3: Individual Stock Analysis - Ganne Pharmaceutical experienced a net outflow of 34.73 million yuan from institutional investors, while retail investors showed a net inflow of 129.36 million yuan, reflecting a divergence in investment strategies [3]. - Other notable stocks included Huashan Biological, which had a net inflow of 430.99 million yuan from institutional investors, indicating positive sentiment towards its performance [3].

证券代码：600211 证券简称：西藏药业 公告编号：2025-046 西藏诺迪康药业股份有限公司 关于以集中竞价方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 17,000 万元（含），不高于人民币 20,000 万元（含）。 3、公司本次回购股份拟在未来适宜时机用于股权激励或员工持股计划，若公司未能在 法律法规规定的期限内实施上述用途，则存在已回购股份全部或部分无法授出从而将被予 以注销的风险。 4、如遇监管部门颁布新的回购相关规范性文件，可能导致本次回购实施过程中需要根 ● 回购股份资金来源：公司自有资金 ● 回购股份用途：用于实施股权激励或员工持股计划。若公司未能在股份回购实施结果暨 股份变动公告日后三年内转让完毕，未转让股份将依法履行相关程序予以注销。 ● 回购股份价格：不超过人民币 55 元/股（含）。该价格不高于公司董事会通过回购股份 决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式 ● 回购股份 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with an amount between 170 million and 200 million yuan, at a price not exceeding 55 yuan per share [1] Group 1: Share Repurchase Details - The repurchase is expected to involve 3,090,909 to 3,636,364 shares, representing 0.96% to 1.13% of the total share capital [1] - The funding for the repurchase will come from the company's own funds [1] - The repurchased shares will be used for equity incentives or employee stock ownership plans, and any shares not transferred within three years will be canceled [1] Group 2: Timeline and Impact - The repurchase will take place within 12 months from the board's approval [1] - The company's directors, supervisors, and controlling shareholders have no plans to reduce their holdings in the next three to six months [1] - The company believes that the repurchase will not have a significant impact on its operations [1]